Hospital
Roswell Hospital Corporation
Roswell Hospital Corporation was paid $41.27M by Medicaid between Jan 2018 and Dec 2024, across 310 billing codes. Its largest line is 99284, emergency room visit (serious) — 14% of everything it billed.
33Billing provider infoROSWELL HOSPITAL CORPORATION
ROSWELL, NM 88201
ROSWELL, NM 88201
33aNPI1447221742assigned 01/27/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$41.27M
24GClaims851,482
24DCodes billed310
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New Mexico
Rank by total paid#6 of 24
Median peer was paid$20.13M
This provider vs. median2.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LALOR, PAULA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 163,327 | $7.29M | |
| 2019 | 114,239 | $5.29M | |
| 2020 | 78,456 | $3.95M | |
| 2021 | 93,365 | $4.74M | |
| 2022 | 134,131 | $6.29M | |
| 2023 | 139,062 | $7.01M | |
| 2024incomplete | 128,902 | $6.70M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 32,780 | 30,626 | $5.76M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 36,897 | 34,875 | $5.61M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 4.3% | 5,166 | 5,072 | $1.79M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.9% | 3,675 | 3,546 | $1.63M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 3.4% | 5,096 | 4,834 | $1.41M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.3% | 6,587 | 6,299 | $1.37M |
| 80053 | Comprehensive metabolic panel | 3.3% | 56,913 | 51,662 | $1.35M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.2% | 6,695 | 6,267 | $1.32M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.4% | 17,355 | 15,345 | $992K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.3% | 2,848 | 2,797 | $959K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 2.3% | 2,352 | 2,311 | $936K |
| G0378 | Hospital observation service, per hour | 2.3% | 2,586 | 2,389 | $935K |
298 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | 1.9% | 15,543 | $770K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.9% | 59,187 | $767K |
| 71045 | Radiologic examination, chest; single view | 1.8% | 15,895 | $729K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.7% | 22,075 | $700K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | 1.7% | 1,563 | $688K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.4% | 5,867 | $578K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.1% | 10,081 | $470K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 1.1% | 361 | $434K |
| 87276 | 1.0% | 12,130 | $422K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,723 | $398K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 12,097 | $366K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,009 | $356K |
| 93458 | <1% | 189 | $296K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,779 | $291K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 11,508 | $290K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 15,990 | $288K |
| 81001 | <1% | 30,527 | $280K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 6,880 | $254K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 206 | $245K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 3,917 | $240K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,087 | $209K |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 2,194 | $185K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 9,650 | $179K |
| 80061 | Lipid panel | <1% | 13,127 | $172K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,067 | $166K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,613 | $165K |
| 87040 | <1% | 3,121 | $161K | |
| 83690 | <1% | 9,837 | $154K | |
| 87070 | <1% | 8,721 | $150K | |
| 91200 | <1% | 1,293 | $150K | |
| 87430 | <1% | 5,644 | $146K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,782 | $139K |
| 93880 | <1% | 1,206 | $137K | |
| 72100 | <1% | 1,653 | $137K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 410 | $130K |
| 82150 | <1% | 7,743 | $129K | |
| 84484 | <1% | 10,840 | $127K | |
| 86756 | <1% | 2,080 | $116K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,562 | $114K |
| 82077 | <1% | 2,618 | $110K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 3,789 | $110K |
| 82550 | <1% | 9,545 | $109K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,592 | $107K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 12,674 | $104K |
| A9270 | Non-covered item or service | <1% | 22,161 | $103K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,392 | $99K |
| 73562 | <1% | 1,225 | $99K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,817 | $97K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,813 | $97K |
| 85610 | <1% | 10,593 | $96K | |
| 82553 | <1% | 8,409 | $95K | |
| 83605 | <1% | 3,397 | $92K | |
| 84703 | <1% | 5,270 | $91K | |
| 73030 | <1% | 1,241 | $91K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 10,383 | $90K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,002 | $89K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,302 | $86K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,268 | $84K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 247 | $83K |
| 71250 | <1% | 503 | $80K | |
| 84439 | <1% | 6,367 | $78K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 236 | $77K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 259 | $77K |
| 85730 | <1% | 7,366 | $76K | |
| 70486 | <1% | 329 | $74K | |
| 83880 | <1% | 3,150 | $69K | |
| 87186 | <1% | 4,129 | $66K | |
| 80074 | <1% | 1,252 | $64K | |
| 83735 | <1% | 5,228 | $64K | |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 541 | $63K |
| 88312 | <1% | 846 | $63K | |
| S5000 | Prescription drug, generic | <1% | 9,359 | $63K |
| 80143 | <1% | 1,616 | $62K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 15,782 | $60K |
| 73610 | <1% | 702 | $59K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 569 | $57K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 102 | $52K |
| J2704 | Injection, propofol, 10 mg | <1% | 8,942 | $52K |
| 73630 | <1% | 858 | $51K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,273 | $51K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 8,343 | $50K |
| 81025 | <1% | 5,067 | $48K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,913 | $47K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 568 | $46K |
| 74018 | <1% | 797 | $46K | |
| 99152 | <1% | 547 | $45K | |
| 59025 | Fetal non-stress test | <1% | 380 | $44K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,640 | $43K |
| 87077 | <1% | 4,233 | $43K | |
| 72040 | <1% | 461 | $41K | |
| 82607 | <1% | 2,805 | $39K | |
| G0381 | Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 650 | $39K |
| 84702 | <1% | 1,522 | $38K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 172 | $37K |
| 85027 | <1% | 3,514 | $35K | |
| 86850 | <1% | 2,775 | $33K | |
| 84481 | <1% | 1,927 | $33K | |
| 87428 | <1% | 729 | $31K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 417 | $30K |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 76 | $30K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 505 | $29K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,322 | $29K |
| 73130 | <1% | 493 | $29K | |
| 82105 | <1% | 1,154 | $28K | |
| 87324 | <1% | 1,302 | $28K | |
| 86703 | <1% | 1,709 | $28K | |
| 73620 | <1% | 413 | $27K | |
| 95816 | <1% | 144 | $27K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 95 | $26K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 12,670 | $25K |
| 93971 | <1% | 359 | $25K | |
| 73120 | <1% | 254 | $25K | |
| 86920 | <1% | 223 | $24K | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 1,664 | $23K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 7,574 | $22K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,842 | $21K |
| 83704 | <1% | 1,552 | $20K | |
| 86592 | <1% | 2,212 | $20K | |
| 82962 | <1% | 4,569 | $20K | |
| 82805 | <1% | 584 | $20K | |
| 72131 | <1% | 65 | $20K | |
| 86140 | <1% | 2,921 | $19K | |
| 85362 | <1% | 827 | $18K | |
| 86900 | <1% | 2,978 | $18K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,119 | $18K |
| 73560 | <1% | 305 | $17K | |
| 93017 | <1% | 239 | $17K | |
| 96376 | <1% | 1,644 | $17K | |
| 87340 | <1% | 860 | $17K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 141 | $16K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 549 | $16K |
| 87522 | Neg quan hep c or qual rna | <1% | 324 | $16K |
| 85651 | <1% | 2,037 | $15K | |
| G0380 | Level 1 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 351 | $15K |
| 76641 | <1% | 111 | $15K | |
| 73110 | <1% | 249 | $15K | |
| 90715 | <1% | 482 | $14K | |
| 83540 | <1% | 1,640 | $13K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,806 | $13K |
| 29125 | <1% | 113 | $12K | |
| 86803 | <1% | 890 | $12K | |
| 73600 | <1% | 121 | $12K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 1,709 | $12K |
| 82728 | <1% | 869 | $12K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 218 | $11K |
| 86038 | <1% | 1,112 | $11K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 879 | $11K |
| 86762 | <1% | 699 | $11K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 99 | $11K |
| 94760 | <1% | 891 | $10K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 43 | $10K |
| 87205 | <1% | 1,297 | $10K | |
| 83550 | <1% | 1,159 | $10K | |
| 86677 | <1% | 492 | $10K | |
| 90714 | <1% | 358 | $10K | |
| 94644 | <1% | 94 | $10K | |
| 86308 | <1% | 512 | $10K | |
| 82140 | <1% | 410 | $10K | |
| 84100 | <1% | 875 | $10K | |
| 36430 | <1% | 79 | $9K | |
| 97161 | <1% | 243 | $9K | |
| 84550 | <1% | 1,109 | $9K | |
| 86901 | <1% | 2,512 | $9K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,780 | $9K |
| 73090 | <1% | 146 | $9K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,773 | $9K |
| 74021 | <1% | 68 | $8K | |
| 82043 | <1% | 2,181 | $8K | |
| 12001 | <1% | 95 | $8K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 73 | $8K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 63 | $7K |
| 93970 | <1% | 68 | $7K | |
| 51702 | <1% | 116 | $7K | |
| 76770 | <1% | 94 | $7K | |
| 86255 | <1% | 314 | $7K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,841 | $7K |
| 76801 | <1% | 61 | $7K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 196 | $6K |
| 86060 | <1% | 253 | $6K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,240 | $6K |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 631 | $6K |
| 77080 | <1% | 69 | $6K | |
| 73100 | <1% | 76 | $6K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,389 | $5K |
| 74178 | <1% | 16 | $5K | |
| C1769 | Guide wire | <1% | 309 | $5K |
| P9047 | Infusion, albumin (human), 25%, 50 ml | <1% | 60 | $5K |
| 36600 | <1% | 305 | $5K | |
| 84153 | <1% | 324 | $4K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 196 | $4K |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 552 | $4K |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 276 | $4K |
| 86235 | <1% | 21 | $4K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,023 | $4K |
| 87045 | <1% | 338 | $4K | |
| 84403 | <1% | 257 | $4K | |
| 73590 | <1% | 77 | $4K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 586 | $4K |
| 82248 | <1% | 987 | $4K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 13 | $3K |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 359 | $3K |
| 80050 | General health panel | <1% | 53 | $3K |
| 82947 | <1% | 558 | $3K | |
| 73502 | <1% | 61 | $3K | |
| 77066 | Tomosynthesis, mammo | <1% | 14 | $3K |
| Q0222 | Injection, bebtelovimab, 175 mg | <1% | 42 | $3K |
| 73140 | <1% | 41 | $3K | |
| 94726 | <1% | 25 | $3K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 198 | $3K |
| 86376 | <1% | 219 | $2K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,236 | $2K |
| 73080 | <1% | 42 | $2K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 324 | $2K |
| J7510 | Prednisolone oral, per 5 mg | <1% | 501 | $2K |
| 94060 | <1% | 25 | $2K | |
| 82570 | <1% | 207 | $2K | |
| 86780 | <1% | 90 | $2K | |
| 97162 | <1% | 39 | $2K | |
| 95812 | <1% | 14 | $2K | |
| 84146 | <1% | 83 | $2K | |
| 87420 | <1% | 107 | $2K | |
| 84466 | <1% | 99 | $2K | |
| 87081 | <1% | 69 | $2K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 16 | $2K |
| 0012A | <1% | 42 | $2K | |
| 84156 | <1% | 230 | $2K | |
| J0153 | Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | <1% | 77 | $2K |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 120 | $2K |
| 86787 | <1% | 211 | $2K | |
| 84402 | <1% | 95 | $2K | |
| 83001 | <1% | 70 | $1K | |
| 86336 | <1% | 73 | $1K | |
| 82670 | <1% | 55 | $1K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 376 | $1K |
| 86141 | <1% | 123 | $1K | |
| 76536 | <1% | 12 | $1K | |
| 87177 | <1% | 166 | $1K | |
| 87338 | <1% | 102 | $1K | |
| 72170 | <1% | 26 | $1K | |
| 82746 | <1% | 127 | $1K | |
| 83615 | <1% | 103 | $1K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 86 | $1K |
| 82390 | <1% | 122 | $1K | |
| 74019 | <1% | 13 | $1K | |
| 86430 | <1% | 166 | $1K | |
| 94729 | <1% | 25 | $1K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 362 | $1K |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 86 | $1K |
| 71111 | <1% | 14 | $1K | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 61 | $1K |
| 73501 | <1% | 14 | $1K | |
| 76010 | <1% | 13 | $975.13 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 328 | $941.22 |
| 82565 | <1% | 107 | $872.34 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 166 | $866.06 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 108 | $802.25 |
| 96367 | <1% | 13 | $782.80 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 88 | $782.25 |
| 83002 | <1% | 41 | $774.77 | |
| 73070 | <1% | 12 | $766.86 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 75 | $730.22 |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 147 | $708.82 |
| 86694 | <1% | 28 | $696.76 | |
| 82010 | <1% | 68 | $689.22 | |
| C1768 | Graft, vascular | <1% | 13 | $652.15 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 45 | $648.69 |
| 81003 | <1% | 262 | $580.89 | |
| G0008 | Administration of influenza virus vaccine | <1% | 27 | $514.46 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 362 | $493.81 |
| 73552 | <1% | 13 | $486.97 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 118 | $486.70 |
| 86225 | <1% | 32 | $468.70 | |
| J1815 | Injection, insulin, per 5 units | <1% | 1,126 | $463.30 |
| 80179 | <1% | 69 | $397.34 | |
| 91301 | <1% | 58 | $369.48 | |
| 82272 | <1% | 87 | $361.03 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 299 | $357.75 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 93 | $356.76 |
| 82247 | <1% | 38 | $348.93 | |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 14 | $326.04 |
| 83525 | <1% | 25 | $291.54 | |
| 86705 | <1% | 21 | $257.91 | |
| 86709 | <1% | 43 | $243.71 | |
| 87210 | <1% | 18 | $189.06 | |
| G9019 | Oseltamivir phosphate, oral, per 75 mg (for use in a medicare-approved demonstration project) | <1% | 16 | $187.44 |
| 89050 | <1% | 44 | $164.50 | |
| J3371 | Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg | <1% | 13 | $156.75 |
| 80069 | <1% | 15 | $141.27 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 16 | $85.44 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 13 | $76.87 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 27 | $72.81 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 12 | $46.67 |
| 82950 | <1% | 13 | $41.22 | |
| 85379 | <1% | 12 | $29.18 | |
| 85007 | <1% | 14 | $28.08 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 28 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 26 | $0.00 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 169 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLALOR, PAULA (DIRECTOR/DELEGATED OFFICIAL)
| Provider | Location | Paid |
|---|---|---|
| Northwest Hospital LLC | Tucson, AZ | $47.81M |
| Wesley Health System LLC | Hattiesburg, MS | $37.82M |
| Metro Knoxville Hma LLC | Powell, TN | $28.70M |
| Bullhead City Hospital Corporation | Bullhead City, AZ | $28.54M |
| Iom Health System LP | Fort Wayne, IN | $27.50M |
| ST. Joseph Health System, LLC | Fort Wayne, IN | $25.43M |
| Laredo Texas Hospital Company LP | Laredo, TX | $19.46M |
| Oak Hill Hospital Corporation | Oak Hill, WV | $18.77M |
| Cocke County Hma, LLC | Newport, TN | $18.34M |
| Cleveland Tennessee Hospital Company LLC | Cleveland, TN | $16.31M |
| Jefferson County Hma LLC | Jefferson City, TN | $14.31M |
| Northwest Arkansas Hospitals, LLC | Springdale, AR | $11.46M |
| Petersburg Hospital Company LLC | Petersburg, VA | $11.20M |
| Campbell County Hma, LLC | Lafollette, TN | $10.07M |
| Warsaw Health System LLC | Warsaw, IN | $9.95M |
| Longview Medical Center LP | Longview, TX | $9.29M |
| Moberly Hospital Company LLC | Moberly, MO | $8.61M |
| Crestview Hospital Company, LLC | Crestview, FL | $8.15M |
| Kirksville Missouri Hospital Company, LLC | Kirksville, MO | $7.98M |
| Victoria of Texas LP | Victoria, TX | $7.74M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.